Kumud P. Bhendarkar

Kumud P. Bhendarkar

Auto-generated profile, based on publicly available information

Kumud P. Bhendarkar

Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur, Maharashtra, 440033, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2026 in In Silico Research in Biomedicine
Verified
Journal Article
Open access
KBKumud P. Bhendarkar
Kumud P. Bhendarkar
DWDeepali M. Wanode
Deepali M. Wanode
PKPramod B. Khedekar
Pramod B. Khedekar

8 April 2026 in Asian Journal of Chemistry
Verified
Journal Article
Open access
KBKumud P. Bhendarkar
Kumud P. Bhendarkar
DWDeepali M. Wanode
Deepali M. Wanode
PKPramod B. Khedekar
Pramod B. Khedekar
In this work, few new pyrazoline derivatives Py1-Py5 were synthesised, characterised and their potential as EGFR kinase inhibitors was assessed. The target compounds were synthesized via Claisen-Schmidt condensation, followed by cyclization of the resulting chalcones using thiosemicarbazide. The anticipated chemical frameworks were confirmed by structural elucidation utilizing IR, 1H NMR, 13C NMR and HRMS studies. All the derivatives showed substantial binding affinities in molecular docking analysis using AutoDock Vina against EGFR kinase (PDB ID: 3POZ). Compound Py3 exhibited the highest docking score (-10.2 kcal/mol), surpassing the co-crystallized ligand O3P (-10.0 kcal/mol) and demonstrated interactions with key EGFR inhibitory residues, including Lys50, Thr95, Met98 and Val131. ADMET projections indicated low toxicity, excellent pharmacokinetic characteristics and synthetic accessibility. Furthermore, compound Py2 had the lowest IC50 value (44.47 µg/mL) in an in vitro cytotoxicity screening against MCF-7 breast cancer cells using the MTT test, indicating considerable activity. The structure-activity relationship analysis suggested that the presence of electron withdrawing substituents, especially chloro and nitro groups, enhances the cytotoxicity activity.

30 June 2025 in Current Cancer Therapy Reviews
Verified
Journal Article
Closed access
PDF file
DWDeepali Wanode
Deepali Wanode
DNDeweshri Nandurkar
Deweshri Nandurkar
RPRohini Palekar
Rohini Palekar
KBKumud Bhendarkar
Kumud Bhendarkar
PKPramod Khedekar
Pramod Khedekar
Angiogenesis reduction with VEGF/VEGFR (Vascular Endothelial Growth Factor/ Vascular Endothelial Growth Factor Receptor) inhibition is the target of our review. Angiogenesis is the development of blood vessels and affects cancer spread and progression. The angiogenesis process is triggered by a number of growth factors, including cytokines, VEGF, FGF (fibroblast growth factor), and PDGF (platelet-derived growth factor). VEGF and VEGFR are two factors that significantly impact the angiogenesis process. VEGFRs are Kinase Domain Receptors (KDRs). Upon activation, KDRs trigger autophosphorylation, which leads to tumor growth, metastasis, and cell proliferation. Numerous cancer types, including breast, renal, non-small cell lung, cervical, hepatocellular, and others, have been linked to overexpression of VEGFR. It has been established that VEGF/ VEGFR overexpression or gene amplification occurs in certain malignancies. Furthermore, an increasing amount of research has shown that blocking VEGF/VEGFR may enhance the effects of chemotherapy. In recent decades, several VEGF/VEGFR inhibitors have been developed that effectively inhibit the growth and progression of several malignancies in vivo and in vitro, suggesting that VEGF/VEGFR could be a novel target for therapeutic intervention. In this review, we started by quickly going over the composition, location, and physiological roles of VEGF/VEGFR during mitosis. The oncogenic function of VEGF/VEGFR in the development of cancer has then been covered. Lastly, we have discussed the prospective anticancer therapy provided by the clinically authorized VEGFR inhibitors.